Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine
- PMID: 9682364
- DOI: 10.1016/s0264-410x(98)80104-7
Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine
Abstract
Gonadal function can be controlled through immunoneutralisation of gonadotrophin releasing hormone (GnRH), with an analogue, GnRH-glycys, linked to a carrier molecule and an appropriate adjuvant. In this study, four different types of carrier molecule were investigated: (a) single and branched amino acid polymers--[poly-(D-glu, D-lys) and poly-(phe, glu)-poly(DL-ala)-poly(lys)]; (b) bacterial toxoids--diphtheria (DT) and tetanus (TT); (c) synthetic T-helper epitopes--derived from malarial circumsporozite protein (CS) and measles virus fusion protein (MVF); and (d) thyroglobulin (Thy)--a large protein. The effect of non-ionic surfactant vesicles (NISV) and an aluminum hydroxide based adjuvant (alum), was also examined. Although good antibody responses were achieved with GnRH-glycys-DT, GnRH-glycys-TT and GnRH-glycys-Thy, adsorbed onto alum and the dimerised synthetic T-helper epitope constructs, incorporated into NISV, a critical antibody titre was necessary to result in morphological changes in the gonads and complete suppression of spermatogenesis. This was only achieved with tetanus toxoid and the dimerised T-helper epitopes.
Similar articles
-
Synthetic gonadotrophin-releasing hormone (GnRH) vaccines incorporating GnRH and synthetic T-helper epitopes.Vaccine. 1993;11(11):1145-50. doi: 10.1016/0264-410x(93)90077-b. Vaccine. 1993. PMID: 7504380
-
Bypass of carrier-induced epitope-specific suppression using a T-helper epitope.Immunology. 1992 Aug;76(4):599-603. Immunology. 1992. PMID: 1383134 Free PMC article.
-
An investigation into the immunogenicity of a GnRH analogue in male rats: a comparison of the toxicity of various adjuvants used in conjunction with GnRH-glycys.Vaccine. 1996 Apr;14(5):451-7. doi: 10.1016/0264-410x(95)00164-v. Vaccine. 1996. PMID: 8735559
-
Glycoconjugate vaccines and immune interference: A review.Vaccine. 2010 Aug 2;28(34):5513-23. doi: 10.1016/j.vaccine.2010.06.026. Epub 2010 Jun 25. Vaccine. 2010. PMID: 20600514 Review.
-
Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines.Vaccine. 1993;11 Suppl 1:S46-51. doi: 10.1016/0264-410x(93)90160-y. Vaccine. 1993. PMID: 8447176 Review.
Cited by
-
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.Front Oncol. 2019 Feb 25;9:49. doi: 10.3389/fonc.2019.00049. eCollection 2019. Front Oncol. 2019. PMID: 30859088 Free PMC article.
-
Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment.Acta Pharm Sin B. 2020 Feb;10(2):262-275. doi: 10.1016/j.apsb.2019.10.010. Epub 2019 Nov 2. Acta Pharm Sin B. 2020. PMID: 32082972 Free PMC article.
-
Current status of veterinary vaccines.Clin Microbiol Rev. 2007 Jul;20(3):489-510, table of contents. doi: 10.1128/CMR.00005-07. Clin Microbiol Rev. 2007. PMID: 17630337 Free PMC article. Review.
-
Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.Oncol Lett. 2016 Aug;12(2):963-970. doi: 10.3892/ol.2016.4679. Epub 2016 Jun 7. Oncol Lett. 2016. PMID: 27446378 Free PMC article.
-
The hinge region fragment of immunoglobulin G improves immunogenicity of recombinant gonadotrophin-releasing hormone conjugated to the T-helper epitope in designing peptide vaccines.Immunology. 2009 Sep;128(1 Suppl):e506-13. doi: 10.1111/j.1365-2567.2008.03020.x. Epub 2008 Nov 24. Immunology. 2009. PMID: 19740311 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical